Mobile App Logging for Diabetes in Pregnancy
Part of paid clinical trials in Augusta, Georgia.
- Sponsor
- Carolyn Zahler-Miller
- Study ID
- NCT06005987
- Status
- Recruiting
Conditions
- Gestational Diabetes Mellitus in Pregnancy
- Type 2 Diabetes
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - 100 Years
- Healthy Volunteers
- Accepted
Interventions
- OneTouch Reveal application — BEHAVIORALEvaluate if compliance with glucose logging and percentage of in range glucoses changes with use of a mobile application instead of paper logging
Study Details
To determine the effect of using a mobile app versus paper logs on compliance and percentage in range blood sugars in monitoring blood sugar in pregnant women with diabetes.
Key Dates
- Start date
- Jun 1, 2024
- Status verified
- Jan 2025
- Primary completion
- Jan 1, 2027
- Completion
- Jan 1, 2027
Study Design
- Enrollment
- 40 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Mobile App armPatient will input their daily blood glucose levels (fasting and 2 hours after breakfast, lunch and dinner) into the OneTouch Reveal app
- No Intervention: Paper Log ArmPatients will input their daily blood glucose levels onto paper logs which is the current process in the prenatal clinic.
Primary Outcome Measure
Compliance [ Time Frame: 4 weeks ]
Central Contacts
- Rebecca Keipper, MD7067212541
- Carolyn M Zahler-Miller, MD7067212543
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Augusta University | Augusta | Georgia | 30912 |
Find similar trials in Augusta, GA
By condition
By specialty
By research site
Related Studies
- Effectiveness and Safety of the RIGHTEST Continuous Glucose Monitoring System for Blood Glucose Management in Persons With Diabetes MellitusNot Yet Recruiting · Bionime Corporation · Guntersville, Alabama
- Glycemic Excursion Minimization (GEM) to Outshine Health DisparitiesRecruiting · Catherine Davis · Augusta, Georgia
- A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)PHASE3 · Recruiting · Eli Lilly and Company · Tucson, Arizona
- A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or TirzepatidePHASE2 · Recruiting · Eli Lilly and Company · Phoenix, Arizona